- Home
- RBRK vs PCVX Comparison
RBRK vs PCVX Comparison
Compare RBRK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBRK
- PCVX
- Stock Information
- Founded
- RBRK 2013
- PCVX 2013
- Country
- RBRK United States
- PCVX United States
- Employees
- RBRK N/A
- PCVX N/A
- Industry
- RBRK
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- RBRK
- PCVX Health Care
- Exchange
- RBRK NYSE
- PCVX Nasdaq
- Market Cap
- RBRK 13.6B
- PCVX 11.5B
- IPO Year
- RBRK 2024
- PCVX 2020
- Fundamental
- Price
- RBRK $69.71
- PCVX $79.74
- Analyst Decision
- RBRK Buy
- PCVX Strong Buy
- Analyst Count
- RBRK 19
- PCVX 8
- Target Price
- RBRK $66.59
- PCVX $127.71
- AVG Volume (30 Days)
- RBRK 1.8M
- PCVX 881.2K
- Earning Date
- RBRK 03-13-2025
- PCVX 02-25-2025
- Dividend Yield
- RBRK N/A
- PCVX N/A
- EPS Growth
- RBRK N/A
- PCVX N/A
- EPS
- RBRK N/A
- PCVX N/A
- Revenue
- RBRK $803,457,000.00
- PCVX N/A
- Revenue This Year
- RBRK $41.45
- PCVX N/A
- Revenue Next Year
- RBRK $28.13
- PCVX N/A
- P/E Ratio
- RBRK N/A
- PCVX N/A
- Revenue Growth
- RBRK 33.22
- PCVX N/A
- 52 Week Low
- RBRK $28.34
- PCVX $58.10
- 52 Week High
- RBRK $80.00
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- RBRK N/A
- PCVX 36.96
- Support Level
- RBRK N/A
- PCVX $82.03
- Resistance Level
- RBRK N/A
- PCVX $84.10
- Average True Range (ATR)
- RBRK 0.00
- PCVX 3.12
- MACD
- RBRK 0.00
- PCVX -0.70
- Stochastic Oscillator
- RBRK 0.00
- PCVX 1.88
About RBRK RUBRIK INC
Rubrik Inc is a company that offers data security solutions to organizations ranging from the largest companies worldwide to mid-sized smaller customers. Its platform is architected to help organizations achieve cyber resilience, which encompasses cyber posture and cyber recovery. They enable organizations to confidently accelerate digital transformation and leverage the cloud to realize business agility.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.